5 | 10 | 15 | |
49 | 26 | 75 | |
54 | 36 | 90 |
TMT A | 53 | 3.12 |
15 | 2.06 (2.23) | 72 | 46 | ||
TMT B | 33 | 2.82 |
13 | 2.76 (2.57) | 82 | 60 | ||
SCOWA | 66 | −1.28 (0.87) | 15 | −0.86 (0.84) | 51 | 27 | ||
SVLT-ir | 65 | −1.98 (1.06) | 15 | −1.15 (1.12) | 71 | 33 | ||
SVLT-sr | 65 | −2.20 (1.29) | 15 | −1.37 (1.22) | 84 | 53 | ||
SVLT-dr | 65 | −2.14 (1.27) | 15 | −0.98 (1.34) | 69 | 33 | ||
SVLT-recog | 65 | −3.06 |
15 | −1.24 (1.91) | 29 | 26 |
Gender | Male | 57 (63%) | |
Female | 33 (37%) | ||
Age | < 50 years | 17 (19%) | M = 58.78, SD = 11.31 |
50–70years | 60 (67%) | ||
> 70 years | 13 (14%) | ||
Education | ≤9 years | 14 (16%) | |
10–13 years | 48 (53%) | ||
14–19 years | 26 (29%) | ||
≥20 years | 2 (2%) | ||
Tumour grade | Grade III | 12 (13%) | |
Grade IV | 78 (87%) | ||
Tumour location | Frontal | 34 (38%) | |
Parietal | 21 (23%) | ||
Temporal | 26 (29%) | ||
Occipital | 4 (4%) | ||
central | 3 (3%) | ||
Diffuse | 2 (2%) | ||
Hemisphere | Right | 38 (42%) | |
Left | 44 (49%) | ||
Both | 8 (9%) | ||
Surgery type | Biopsy | 11 (12%) | |
Reduction | 49 (54%) | ||
Gross tumour resection | 30 (33%) | ||
Karnoffsky performance status | 70 | 32 (36%) | |
80 | 37 (41%) | ||
90 | 18 (20%) | ||
100 | 3 (3%) | ||
Corticosteroids (Yes/no, mg) | Yes | 66 (73%) | M = 5.55, SD = 4.73 |
No | 24 (27%) | ||
Radio-chemotherapy (intention to treat) | Yes | 90 (100%) | |
No | 0 (0%) | ||
Time to beginning of adjuvant treatment (in weeks) | ≤ 6 weeks | 60 (67%) | M = 5.98, SD = 2.25 |
≥ 7 weeks | 30 (33%) | ||
Epilepsy | Yes | 27 (30%) | |
No | 63 (70%) | ||
IDH1 mutation | IDH1 mutation | 15 (17%) | |
IDH1 wild type | 75 (83%) | ||
MGMT methylation* | Yes | 36 (42%) | |
No | 50 (58%) |
Age mean (min/max/SD) | 61.50 (31 / 84 / 9.21) | 38.75 (30 / 67 / 3.86) | |
Sex (female / male) | 29 / 46 | 4 / 11 | |
Education level (≤ 9 years /10–13 years / 14–19 years / ≥ 20 years) | 11 / 40 / 22 / 2 | 3 / 8 / 4 / 0 | |
KPS (70/80/90/100) | 31 / 34 / 7 / 3 | 1 / 3 / 11 / 0 | |
WHO grade (III / IV) | 1 /74 | 11 /4 | |
Corticosteroids mg (min/max/SD) | 2 (0 / 16 / 6) | 5 (0 / 24 / 4.5) | |
biopsy/reduction/gross tumour resection | 9 / 44 / 22 | 2 / 5 / 8 | |
Tumour location (frontal / temporal / parietal / occipital / diffuse / central) | 26 / 20 / 21 / 4 / 2 / 2 | 8 / 1 / 5 / 0 / 1 / 0 | NA |
Hemisphere (right / left / both) | 21 / 27 / 6 | 17 / 17 / 2 | |
MGMT (yes / no) | 10 / 5 | 26 /49 |
TMT A | 26 | 2.67 (3.01) | 42 | 3.03 |
69 | 66 | ||
TMT B | 20 | 3.22 (2.30) | 26 | 2.48 |
86 | 74 | ||
SCOWA | 33 | −1.25 (0.87) | 48 | −1.18 |
50 | 44 | ||
SVLT-ir | 32 | −1.85 (1.27) | 48 | −1.82 |
64 | 67 | ||
SVLT-sr | 32 | −2.03 (1.32) | 48 | −2.06 (1.32) | 75 | 81 | ||
SVLT-dr | 32 | −1.98 (1.52) | 48 | −1.89 (1.25) | 66 | 61 | ||
SVLT-recog | 32 | −2.731 (4.24) | 48 | −2.72 |
58 | 61 |
Age mean (min/max/SD) | 58.94 (31 / 84 / 10.42) 1 | 58,53 (30 / 78 / 12.67) | |
Sex (female / male) | 19 / 35 | 14 / 22 | |
Education level (≤9 years /10–13 years / 14–19 years / ≥ 20 years) | 8 / 19 / 11 / 0 | 9 / 29 / 15 / 2 | |
KPS (70/80/90/100) | 20 / 23 / 9 / 2 | 12 / 14 / 9 /1 | |
WHO grade (III / IV) | 3 / 51 | 9 / 27 | |
Corticosteroids mg (min/max/SD) | 5.67 (0 /24 / 5,04) | 5.48 (0 / 16 / 4.22) | |
Biopsy/reduction/gross tumour resection | 9 / 31 / 14 | 2 / 18 / 16 | |
Tumour location (frontal / temporal / parietal / occipital / diffuse / central) | 26 / 20 / 21 / 4 / 2 / 2 | 8 / 1 / 5 / 0 / 1 / 0 | NA |
Hemisphere (right / left / both) | 28 / 40 / 7 | 10 / 4 / 1 | |
IDH1 (yes / no) | 5 / 49 | 10 / 26 |
Visual – motor speed | TMT A | 68 | 68 | 57 | 2.89 | 3.57 |
Executive function | TMT B | 78 | 46 | 59 | 2.80 | 2.94 |
Verbal fluency | SCOWA | 47 | 81 | 41 | −1.21 | 0.88 |
Memory | ||||||
immediate recall | SVLT-ir | 64 | 80 | 60 | −1.83 | 1.11 |
short delayed recall | SVLT-sr | 79 | 76 | −2.05 | 1.31 | |
delayed recall | SVLT-dr | 63 | 58 | −1.92 | 1.35 | |
recognition | SVLT-recog | 60 | 52 | −2.73 | 3.36 |